Compare GTX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTX | LGND |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | GTX | LGND |
|---|---|---|
| Price | $18.18 | $190.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $20.00 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 2.4M | 240.2K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 55.30 | 0.76 |
| EPS | 1.57 | ★ 2.49 |
| Revenue | ★ $3,537,000,000.00 | $251,233,000.00 |
| Revenue This Year | $3.71 | $47.71 |
| Revenue Next Year | $3.41 | $9.77 |
| P/E Ratio | ★ $11.60 | $76.97 |
| Revenue Growth | N/A | ★ 64.83 |
| 52 Week Low | $7.02 | $93.58 |
| 52 Week High | $19.28 | $212.49 |
| Indicator | GTX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 47.99 |
| Support Level | $18.14 | $188.80 |
| Resistance Level | $18.67 | $202.79 |
| Average True Range (ATR) | 0.48 | 6.95 |
| MACD | -0.04 | -0.43 |
| Stochastic Oscillator | 79.02 | 28.64 |
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.